Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System

Resistance to platinum chemotherapy is one of the main factors driving ovarian cancer mortality, and overcoming platinum resistance is considered one of the greatest challenges in ovarian cancer research. Genetic and functional evidence points to the homologous recombination (HR) DNA repair system, and BRCA1 and BRCA2 in particular, as main determinants of response to platinum therapy. BRCA-mutant ovarian cancers are especially sensitive to platinum, associated with better survival, and amenable to poly ADP ribose polymerase inhibitor treatment. Here, we discuss a therapeutic concept that seeks to disrupt HR capacity via targeting of BRCA1 and BRCA2 functionality in order to reverse platinum resistance in BRCA-proficient high-grade serous ovarian cancers (HGSOC). We review the molecular signaling pathways that converge on BRCA1 and BRCA2, their activation status in ovarian cancer, and therapeutic options to modulate BRCA function. Several recent publications demonstrate efficient chemosensitization of BRCA-proficient cancers by combining targeted therapy with standard platinum-based agents. Due to its inherent genomic heterogeneity, molecularly defined subgroups of HGSOC may require different approaches. We seek to provide an overview of available agents and their potential use to reverse platinum resistance by inhibiting the HR system, either directly or indirectly, by targeting oncogenic activators of HR.

[1]  S. Johnson,et al.  Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.

[2]  S. Reed,et al.  Association of human cyclin E with a periodic G1-S phase protein kinase. , 1992, Science.

[3]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[4]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  O. Olopade,et al.  c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells , 2011, BMC Cancer.

[6]  Ook.,et al.  CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER , 2000 .

[7]  H. Hemmi,et al.  A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer , 2001, British Journal of Cancer.

[8]  M. Harrison.  TARGETED THERAPIES IN OVARIAN CANCER , 2008 .

[9]  R. Fisher,et al.  Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. , 1979, Cancer treatment reports.

[10]  E. Friedman,et al.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[12]  T. Volkert,et al.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. , 2002, Genes & development.

[13]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[14]  C. Croce,et al.  Positive Regulation of the BRCA1 Promoter* , 1999, The Journal of Biological Chemistry.

[15]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[16]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[17]  W. Hahn,et al.  Synthetic lethality between CCNE1 amplification and loss of BRCA1 , 2013, Proceedings of the National Academy of Sciences.

[18]  M. Barbacid,et al.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.

[19]  S. West,et al.  CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair , 2005, Nature.

[20]  Andrei Seluanov,et al.  DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells , 2008, Cell cycle.

[21]  E. Atlas,et al.  GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter. , 2000, Oncogene.

[22]  James M. Roberts,et al.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family , 1991, Cell.

[23]  E. Berns,et al.  BMC Cancer BioMed Central Research article Mismatch repair and treatment resistance in ovarian cancer , 2022 .

[24]  Hirotaka Yamamoto,et al.  Role of the transcription factor Ets-1 in cisplatin resistance. , 2004, Molecular cancer therapeutics.

[25]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[26]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[27]  S. Dhanasekaran,et al.  A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. , 2008, Cancer research.

[28]  D. Alberts,et al.  Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Johnston,et al.  BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy , 2007, Clinical Cancer Research.

[30]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[31]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[32]  M. Piccart,et al.  Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  J. Smyth,et al.  Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. , 2005, Cancer research.

[34]  G. Feldmann,et al.  Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models , 2011, Cancer biology & therapy.

[35]  V. Bohr,et al.  ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. , 1992, Journal of the National Cancer Institute.

[36]  Travis J Cohoon,et al.  Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[37]  Pierre Dubus,et al.  Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.

[38]  D. Alberts,et al.  Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Kentaro Nakayama,et al.  Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer , 2010, Cancer.

[40]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Conti,et al.  Lack of Cyclin-Dependent Kinase 4 Inhibits c-myc Tumorigenic Activities in Epithelial Tissues , 2004, Molecular and Cellular Biology.

[42]  Heinz Ruffner,et al.  BRCA1 Is Phosphorylated at Serine 1497 In Vivo at a Cyclin-Dependent Kinase 2 Phosphorylation Site , 1999, Molecular and Cellular Biology.

[43]  T. Ouchi,et al.  The BRCA2 gene product functionally interacts with p53 and RAD51. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Barker,et al.  AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts , 2009, Molecular Cancer Therapeutics.

[45]  L. Lagasse,et al.  cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. , 1979, Cancer treatment reports.

[46]  Kwok-Kin Wong,et al.  COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION , 2011, Nature Medicine.

[47]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[48]  F. Couch,et al.  Induction of the BRCA2 promoter by nuclear factor-kappa B. , 2000, The Journal of biological chemistry.

[49]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[50]  Punit Marathe,et al.  N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. , 2004, Journal of medicinal chemistry.

[51]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  J. Downward,et al.  Heregulin Induces Phosphorylation of BRCA1 through Phosphatidylinositol 3-Kinase/AKT in Breast Cancer Cells* , 1999, The Journal of Biological Chemistry.

[54]  I. Vergote,et al.  A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  K. Helin,et al.  E2F target genes: unraveling the biology. , 2004, Trends in biochemical sciences.

[56]  T. Lyons,et al.  AKT regulates BRCA1 stability in response to hormone signaling , 2010, Molecular and Cellular Endocrinology.

[57]  P. Davis,et al.  Isolation and initial characterization of the BRCA2 promoter , 1999, Oncogene.

[58]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[59]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[60]  A. Sood,et al.  Overcoming platinum resistance in ovarian carcinoma , 2010, Expert opinion on investigational drugs.

[61]  S. Reed,et al.  Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. , 1992, Genes & development.

[62]  Chun-Fang Xu,et al.  Complex Regulation of the BRCA1 Gene* , 1997, The Journal of Biological Chemistry.

[63]  J. Nevins,et al.  The E2F1–3 transcription factors are essential for cellular proliferation , 2001, Nature.

[64]  J. Parvin,et al.  Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. , 2009, Molecular cell.

[65]  P. Atadja,et al.  Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells , 2012, Molecular Cancer Therapeutics.

[66]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[67]  Brigitte M. Ronnett,et al.  The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[68]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[69]  Steven P Gygi,et al.  Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response , 2007, Science.

[70]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[71]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[72]  Nidhi Sharma,et al.  Cell proliferation in the absence of E2F1-3. , 2011, Developmental biology.

[73]  M. Macleod,et al.  Regulation of BRCA1 Expression by the Rb-E2F Pathway* , 2000, The Journal of Biological Chemistry.

[74]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[75]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[76]  F. Couch,et al.  Induction of the BRCA2 Promoter by Nuclear Factor-κB* , 2000, The Journal of Biological Chemistry.

[77]  S. Elledge,et al.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. , 1992, Science.

[78]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[79]  Kylie L. Gorringe,et al.  Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer , 2010, PloS one.

[80]  P. Borst,et al.  How do real tumors become resistant to cisplatin? , 2008, Cell cycle.

[81]  P. Meltzer,et al.  Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer , 2013, Genome research.

[82]  M. Roussel,et al.  Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. , 1994, Oncogene.

[83]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[84]  J. Castellví,et al.  Analysis of Gene Expression Regulated by the ETV5 Transcription Factor in OV90 Ovarian Cancer Cells Identifies FOXM1 Overexpression in Ovarian Cancer , 2012, Molecular Cancer Research.

[85]  Ralph Scully,et al.  Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage , 1997, Cell.

[86]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[87]  G. Leone,et al.  Division and apoptosis of E2f-deficient retinal progenitors , 2009, Nature.

[88]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[89]  S. Modesitt,et al.  A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[90]  Maximina H. Yun,et al.  CtIP-BRCA1 modulates the choice of DNA double-strand break repair pathway throughout the cell cycle , 2009, Nature.

[91]  H. Hochster,et al.  A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity , 2013, Cancer Chemotherapy and Pharmacology.

[92]  D. Stewart,et al.  Mechanisms of resistance to cisplatin and carboplatin. , 2007, Critical reviews in oncology/hematology.

[93]  L. Chodosh,et al.  Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[94]  F. Couch,et al.  Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. , 1998, Molecular cell.

[95]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[96]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[97]  S. Powell,et al.  BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.

[98]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[99]  N. Wentzensen,et al.  Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. , 2011, International journal of cancer.

[100]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[101]  A. Futreal,et al.  BRCA1 expression is not directly responsive to estrogen , 1997, Oncogene.

[102]  S. Rubin,et al.  A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[103]  Yonghong Xiao,et al.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.

[104]  V. Velculescu,et al.  Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.

[105]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[106]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[107]  Lisa M Harlan-Williams,et al.  BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation , 2012, Proceedings of the National Academy of Sciences.